Translational Oncology Training Program

总结 癌症是美国第二大死亡原因，许多挑战仍然存在，以发现新的， 更有效的方法来治愈这种毁灭性的疾病，这需要大力翻译基本的 科学知识走进诊所为了实现这一目标，并进一步促进转化癌症研究， 必须建立一个可持续的计划，以培训和教育下一代科学家， 临床医生，谁必须有广泛的知识和沟通能力，并与同事在这两个 领域的转化肿瘤学培训计划（TOTP）的目标是确保下一个 一代癌症研究人员配备了工具和知识，使他们能够 将实验室发现带入临床试验，反之亦然。这个项目的研究员和学生 将接受四个不同但高度集成的主题的独特培训：临床前建模（PCM）;癌症 图像引导（CIG）;癌症生物验证（CBV）;和临床翻译（CLT）。PCM专注于分析 使用各种临床前模型研究肿瘤进展中涉及的通路和信号传导， 潜在的治疗靶点和生物标志物。CIG提供最先进的图像引导诊断培训 方法和纳米技术为基础的药物输送系统。CBV的学员将学习最新的 多组学环境中的生物信息学技能，以研究和分析大型队列患者数据库。 CLT的指导者有丰富的临床试验经验，他们提供了如何翻译的指导 基础知识应用到临床试验中。学员将在第一年轮流学习四个主题中的三个主题 同时接受四个主题的教学讲座。他们还将组建一个由两人组成的指导小组， 博士和MD教师。该T32计划的大多数导师都在血液学/肿瘤学， 癌症生物学系。这种结构融合了强大的临床和基础科学实体在唤醒 Forest Baptist Comprehensive Cancer Center（WFBCCC）然而，这个培训项目是多学科的 总共有十一个部门的老师。该计划是独特的许多创新的培训 工具：（i）高度整合的4个翻译主题，包括教学讲座和动手旋转 （二）包括博士博士后和医学博士研究员，以促进从临床到临床的研究， 从床边到台式转化癌症研究;（iii）由博士和博士组成的个性化导师团队 （iv）为受训人员提供临床试验准备的靴子训练营;（v）由疾病导向 （六）向独立过渡方案，以支持受训人员成为 通过准备K类申请而独立;和（七）基础广泛的职业机会， 研究生的博士/MBA等发展计划。因此，通过这个培训项目，博士 研究员/学生将学习如何将基础科学知识带到床边，而MD研究员将有 更深入地理解翻译，假设驱动的研究。

Summary Cancer is the second leading cause of death in the US, and many challenges still remain to discover novel and more effective approaches to cure this devastating disease, which requires strong effort in translating basic science knowledge into clinics. To accomplish this goal and further promote translational cancer research, it is imperative to establish a sustainable program to train and educate the next generation of scientists and clinicians, who must have broad knowledge and the ability to communicate and work with colleagues in both fields. The goal of the Translational Oncology Training program (TOTP) is to ensure that the next generation of cancer researchers are equipped with the tools and knowledge that will enable them to bring bench-top discoveries into clinical trials and vice versa. The fellows and students in this program will receive unique training in four different but highly integrated themes: Preclinical Modeling (PCM); Cancer Image Guidance (CIG); Cancer Bio-Validation (CBV); and Clinical Translation (CLT). PCM focuses on analysis of pathways and signaling involved in tumor progression using various preclinical models in order to identify potential therapeutic targets and biomarkers. CIG provides training in state of the art image-guided diagnostic approaches and nanotechnology-based drug delivery systems. Trainees in CBV will learn up-to-date bioinformatics skills in multi-omics setting in order to study and analyze large cohort patient database. Preceptors in CLT have ample experiences in clinical trials and they provide guidance on how to translate basic knowledge into clinical trials. Trainees will rotate through three out of four themes during the first year while taking didactic lectures from all four themes. They will also assemble a mentoring team consisting of both Ph.D and MD faculty. The majority of preceptors of this T32 program are in the Hematology/Oncology and Cancer Biology departments. This structure merges strong clinical and basic science entities in the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC). However, this training program is multidisciplinary and in all, preceptors come from 11 different departments. The program is unique with many innovative training tools: (i) highly integrated 4 translational themes that include both didactic lectures and hands-on rotations among the themes; (ii) inclusion of both Ph.D postdocs and MD fellows to promote both bench-to-bedside and bedside-to-benchtop translational cancer research; (iii) an individualized mentor team consisting of both Ph.D and MD faculty; (iv) boot camp for clinical trial preparation for trainees (v) support from Disease Oriented Teams (DOTs) from WFBCCC; (vi) Transition to Independence (TTI) program to support trainees to become independent through preparation for K-type applications; and (vii) Broad-base career opportunities and development plans such as Ph.D/MBA for graduate students. Therefore, through this training program, Ph.D fellows/students will learn how they can bring basic science knowledge into bedside, while MD fellows will have a deeper understanding of translational, hypothesis-driven research.